{"id":"buthalital","rwe":[{"pmid":"29250413","year":"2017","title":"Buthalital and methitural - 5,5-substituted derivatives of 2-thio-barbituric acid forming the same type of hydrogen-bonded chain.","finding":"","journal":"Acta crystallographica. Section E, Crystallographic communications","studyType":"Clinical Study"}],"tags":[{"label":"buthalital","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"baylinal","offLabel":[],"synonyms":["buthalital","baylinal","buthalial","buthalitone","thialbutone","buthalital sodium"],"timeline":[],"brandName":"Baylinal","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"buthalital","explanation":"Imagine your brain is like a busy city with many different neighborhoods. Baylinal helps calm down the activity in certain neighborhoods, making you feel more relaxed and sleepy. This is achieved by influencing the way neurons communicate with each other, ultimately leading to a decrease in alertness and consciousness.","oneSentence":"Baylinal works by interacting with the central nervous system to produce a sedative effect.","technicalDetail":"Baylinal is a barbiturate derivative that acts as a central nervous system depressant, likely through the modulation of GABA receptors and/or the inhibition of glutamate release."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3054","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BUTHALITAL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:06:41.261228","biosimilars":[],"competitors":[],"genericName":"buthalital","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"K5VBQ75636","CHEBI":"CHEBI:134980","INN_ID":"565","UMLSCUI":"C0602063","ChEMBL_ID":"CHEMBL2110937","PUBCHEM_CID":"3032321","SECONDARY_CAS_RN":"510-90-7","MESH_SUPPLEMENTAL_RECORD_UI":"C004455"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":1,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"recentPublications":[{"date":"2017 Dec 1","pmid":"29250413","title":"Buthalital and methitural - 5,5-substituted derivatives of 2-thio-barbituric acid forming the same type of hydrogen-bonded chain.","journal":"Acta crystallographica. Section E, Crystallographic communications"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Baylinal (BUTHALITAL) is a small molecule buthalital drug with unknown target and commercial status. Its mechanism of action is not well-documented, and it is not FDA-approved for any indications. As a result, there is limited information available on its pharmacokinetics, safety, and efficacy. Further research is needed to fully understand the properties and potential uses of Baylinal. Its current status as a developmental compound makes it difficult to assess its clinical utility.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}